Abstract
Polycystic ovary syndrome (PCOS) is possibly the most common endocrinopathy of reproductive age, characterized by hyperandrogenism and oligomenorrhea. Additionally, approximately one-third to one-half of all women and adolescent girls with PCOS tend to fulfill many of the metabolic syndrome criteria, and many view PCOS as a premetabolic syndrome condition, predisposing to a high risk for cardiovascular disease. Endothelial dysfunction, impaired arterial structure, or proinflammatory markers are early features of atherosclerosis, and can be used as surrogate indicators of future coronary artery disease in women with PCOS. However, as the latest studies show, these symptoms are the result of deleterious effects that cardiovascular risk factors, in particular insulin resistance and obesity, produce on the vascular wall, rather than to the presence of PCOS per se. The relationship between hyperandrogenemia and the risk of cardiovascular disease is controversial and needs to be clarified. Further research is warranted to understand the pathogenesis of cardiovascular disease in PCOS, and to identify subtypes of PCOS in which the presence of cardiovascular risk factors may result in increased cardiovascular events, leading to high morbidity or mortality rates caused by cardiovascular disease.
Similar content being viewed by others
References
Cussons A.J., Stuckey B.G.A., Watts G.F., Cardiovascular disease in the polycystic ovary syndrome: New insights and perspectives, Atherosclerosis, 2006, 185, 227–239
Azziz R., Nestler J., Dewailly D., Androgen excess disorders in women: polycystic ovary syndrome and other disorders, 2nd ed., 2006, Humana Press
Tarkun I., Arslan B.C., Cantürk Z., Türemen E., Sahin T., Duman C., Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation, J. Clin. Endocrinol. Metab., 2004, 89, 5592–5596
Essah P., Wickham E., Nestler J., The metabolic syndrome in polycystic ovary syndrome, Clin. Obstretics and Gynecology, 2007, 1, 205–225
Lorenz L., Wild R., Polycystic ovarian syndrome: an evidence-based approach to evaluation and management of diabetes and cardiovascular risks for today’s clinician, Clin. Obstretics and Gynecology, 2007, 1, 226–243
Hoffman L.K., Ehrmann D.A., Cardiometabolic features of polycystic ovary syndrome, Nat. Clin. Pract. Endocrinol. Metab., 2008, 4, 215–222
Shaw L.J., Bairey Merz C.N., Azziz R., Stanczyk F.Z., Sopko G., Braunstein G.D., et al, Post-Menopausal Women with a History of Irregular Menses and Elevated Androgen Measurements at High Risk for Worsening Cardiovascular Event-Free Survival: Results from the National Institutes of Health-National Heart, Lung, and Blood Institute Sponsored Women’s Ischemia Syndrome Evaluation, J. Clin. Endocrin.Metab., 2008, 93, 1276–1284
Calles-Escandon J., Cipolla M., Diabetes and endothelial dysfunction: a clinical perspective, Endocrine Reviews. 2001, 22, 36–52
Caballero E., Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease, Obesity Research, 2003, 11, 1278–1289
Meyer C., McGrath B., Cameron J., Kotsopoulos D., Teede H.J., Vascular dysfunction and metabolic parameters in polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 4630–4635
Verma S., Anderson T.J., Fundamentals of endothelial function for the clinical cardiologist, Circulation, 2002, 105, 546–549
Quyyumi A.A., Endothelial function in health and disease: new insights into the genesis of cardiovascular disease, Am. J. Med., 1998, 105, 32S–39S
Kravariti M., Naka K.K., Kalantaridou S.N., Kazakos N., Katsouras C.S., Makrigiannakis A., et al., Predictors of endothelial dysfunction in young women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 5088–5095
Orio F.J., Palomba S., Cascella T., De Simone B., Di Biase S., Russo T., et al., Early impairment of endothelial structure and function in young normalweight women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2004, 89, 4588–4593
Diamanti-Kandarakis E., Alexandraki K., Protogerou A., Piperi C., Papamichael C., Aessopos A., et al., Metformin administration improves endothelial function in women with polycystic ovary syndrome, Eur. J. Endocrinol., 2005, 152, 749–756
Tarkun I., Cetinarsian B., Turemen E., Sahin T., Canturk Z., Komsuoglu B., Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial dysfunction in non-obese young women with polycystic ovary syndrome, Eur. J. Endocrinol., 2005, 153, 115–21
Sorensen M.B., Frankst S., Robertson C., Penemm D.J., Collins P., Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors, Clin. Endocrinol., 2006, 65, 655–659
Paradisi G., Steinberg H.O., Hempfling A., Cronin J., Hook G., Shepard M.K. et al., Polycystic ovary syndrome is associated with endothelial dysfunction, Circulation, 2001, 103, 1410–1415
Paradisi G., Steinberg H.O., Shepard M.K., Hook G., Baron A.D., Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2003, 88, 576–580
Kelly C.J., Speirs A., Gould G.W., Petrie J.R., Lyalll H., Connell J.M.C., Altered vascular function in young women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2002, 87, 742–746
Bickerton A.S., Clark N., Meeking D., Shaw K.M., Crook M., Lumb P., et al, Cardiovascular risk in women with polycystic ovarian syndrome (PCOS), J. Clin. Pathol. 2005, 58, 151–154
Carmassi F., Negri F.D., Fioriti R., De Giorgi A., Giannarelli C., Fruzzetti F., et al, Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome, Thrombosis Research, 2005, 116, 207–214
Verma S., Buchanan M.R., Anderson T.J., Endothelial function testing as a biomarker of vascular disease, Circulation, 2003, 108, 2054–2059
Nacul A.P., Andrade C.D., Schwarz P., Homem de Bittencourt Jr P.I., Spritzer P.M., Nitric oxide and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity, Europ. J. Obstet. Gynecol., 2007, 133, 191–196
Dubin D., Pratt R.E., Cooke J.P., Dzau V.J., Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen, J. Vasc. Med. Biol., 1989, 1, 13–16
Diamanti-Kandarakis E., Spina G., Kouli C., Migdalis I., Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy, J. Clin. Endocrinol. Metab., 2001, 86, 4666–4673
Orio F.J., Palomba S., Cascella T., De Simone B., Manguso F., Savastano S., et al., Improvement in endothelial structure and function after metformin treatment in young normal-weigt women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 6072–6076
Talbott E.O., Guzick D.S., Sutton-Tyrrell K., McHugh-Pemu K.P., Zborowski J.V., Remsberg K.E., et al., Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women, Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2414–2421
Vural B., Caliskan E., Turkoz E., Kilic T., Demirci A., Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome, Hum. Reprod., 2005, 20, 2409–13
Carmina E., Orio F., Palomba S., Longo R.A., Cascella T., Colao A., et al., Endothelial dysfunction in PCOS: role of obesity and adipose hormones, Am. J. Medicine., 2006, 119, 356.e1–356.e6
Christian R.C., Dumesic D.A., Behrenbeck T., Oberg A.L., Sheedy II P.F., Fitzpatrick L.A., Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2003, 88, 2562–2568
Talbott E.O., Zborowski J.V., Rager J.R., Boudreaux M.Y., Edmundowicz D.A., Guzick D.S., Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2004, 89, 5454–5461
Meyer C., McGrath B.P., Teede H.K., Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease, J. Clin. Endocrinol. Metab., 2005, 90, 5711–5716
Kershaw E.E., Flier J.S., Adipose tissue as an endocrine organ, J. Clin. Endocrinol. Metab., 2004, 89, 2548–2556
Zhang Y., Yang Y., Hong J., Gu W., Shen C., Xu M., et al., Elevated serum levels of Interleukin-18 are associated with insulin resistance in women with polycystic ovary syndrome, Endocrine, 2006, 29, 3, 419–423
Escobar-Morreale H.F., Botella-Carretero J.I., Villuendas G., Sancho J., San Millan J.L., Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity, J. Clin. Endocrinol. Metab., 2004, 89, 806–811
Linscheid P., Seboek D., Nylen E.S., Langer I., Schlatter M., Becker K.L., et al., In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue, Endocrinology, 2003, 144, 5578–5584
Linscheid P., Seboek D., Schaer D.J., Zulewski H., Keller U., Muller B., Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophageactivated adipocytes, Crit. Care. Med., 2004, 32, 1715–1721
Pai J.K., Pischon T., Ma J., Manson J.E., Hankinson S.E., Joshipura K., et al., Inflammatory markers and the risk of coronary heart disease in men and women, N. Engl. J. Med., 2004, 351, 2599–2610
Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., et al., C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease, N. Engl. J. Med., 2004, 350, 1387–1397
Yudkin J.S., Kumari M., Humphries S.E., Mohamed-Ali V., Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?, Atherosclerosis., 2000, 148:209–14
Olszanecka-Glinianowicz M., Banas M., Zahorska-Markiewicz B., Janowska J., Kocelak P., Madej P., et al., Is the polycystic ovary syndrome associated with chronic inflammation per se?, Eur. J. Obstet. Gynecol. Reprod. Biol., 2007, 133, 197–202
Blankenberg, S., Tiret L., Bickel C., Peetz D., Cambien F., Meyer J., et al., Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina, Circulation, 2002, 106, 24–30
Esposito K., Pontillo A., Ciotola M., Di Palo C., Grella E., Nicoletti G., et al., Weight loss reduces interleukin-18 levels in obese women, J. Clin. Endocrinol. Metab., 2002, 87, 3864–3866
Devaraj S., Xu D.Y., Jialal I., C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aorthic endothelial cells: implications for the metabolic syndrome and atherothrombosis, Circulation, 2003, 107, 398–404
Wang C.H., Li S.H., Weisel R.D., Fedak P.W., Dumont A.S., Szmitko P., et al., C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle, Circulation, 2003, 107, 1783–1790
Kelly C.C., Lyah H., Petrie J.R., Gould G.W., Connell J.M., Sattar N., Low grade chronic inflammation in women with polycystic ovarian syndrome, J. Clin. Endocrinol. Metab., 2001, 86, 2453–2455
Talbott E.O., Zborowski J.V., Boudreaux M.Y., McHugh-Pemu K.P., Sutton-Tyrrell K., Guzick D.S., The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2004, 89, 6061–6067
Orio F. Jr., Palomba S., Cascella T., Di Biase S., Manguso F., Tauchmanova L., et al., The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 2–5
Morin-Papunen L., Rautio K., Ruokonen A., Hedeberg P., Puukka M., Tapanainen J.S., Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2003, 88, 4649–4654
Diamanti-Kandarakis E., Paterakis T., Alexandraki K., Piperi C., Aessopos A., Katsikis I., et al., Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin, Hum. Reprod., 2006, 21, 1426–1431
Diamanti-Kandarakis E., Alexandraki K., Piperi C., Protogerou A., Katsikis I., Paterakis T., et al., Inflammatory and endothelial markers in women with polycystic ovary syndrome, Eur. J. Clin. Invest., 2006, 36, 691–697
Ibanez L., Jaramillo A.M., Ferrer A., de Zegher F., High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception, Hum. Reprod., 2005, 20, 2457–2462
Orio F., Manguso F., Di Biase S., Falbo A., Giallauria F., Labella D., et al., Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study, Eur. J. Endocrinol., 2007, 157, 69–73
Steinberg H.O., Baron A.D., Vascular function, insulin resistance and fatty acids, Diabetologia, 2002, 45, 623–634
Caballero E., Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation, Archives of Medical Research, 2005, 36, 241–249
Diamanti-Kandarakis E., Paterakis T., Kandarkis H.A., Indices of low-grade inflammation in polycystic ovary syndrome, Ann. N.Y. Acad. Sci., 2006, 1092, 175–186
Mohlig M., Spranger J., Osterhoff M., Ristow M., Pfeiffer A.F.H., Schill T., et al, The polycystic ovary syndrome per se is not associated with increased chronic inflammation, Eur. J.Endocrinol., 2004, 150, 525–532
Puder J.J., Varga S., Kraenzlin M., De Geyter C., Keller U., Muller B., Central fat excess in polycystic ovary syndrome: reltion to low-grade inflammation and insulin resistance, J. Clin. Endocrinol. Metab., 2005, 90, 6014–6021
Kearney M.T., Duncan E.R., Kahn M., Wheatcroft S.B., Insulin resistance and endothelial cell dysfunction: studies in mammalian models, Exp Physiol, 2008, 93, 158–163
Katusic Z., Vascular endothelial dysfunction: does tetrahydrobiopterin play a role?, Am. J. Physiol. Heart Circ. Physiol., 2001, 281, H981–H986
Nystrom T., Nygren A., Sjoholm A., Tetra-hydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease, Am. J. Physiol. Endocrinol. Metab., 2004, 287, E919–E925
Carvalheira J.B.C., Calegari V.C., Zecchin HG., Nadruz V., Guimaraes R.B., Ribeiro E.B., et al., The crosstalk between insulin and angiotensin and insulin differentially affects phosphatidylinositol 3-kinase-and mitogen-activated protein kinasemediated signaling in rat heart: implications for insulin resistance, Endocrinology, 2003, 144, 5604–5614
Andreozzi F., Laratta E., Sciacqua A., Perticone F., Sesti G., Angiotensin II impairs the insulin signaling pathaway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser 312 and Ser 616 in human umbilical vein endothelial cells, Circulation Research, 2004, 94, 1211–1218
Piatti P.M., Monti L.D., Galli L., Fragasso G., Valsecchi G., Conti M., et al., Relationship between endothelin-1 concentrations and metabolic alterations typical of the insulin resistance syndrome, Metabolism, 2000, 49,748–752
Kim Jeong-a, Montagnani M., Koh K.K., Quon M.J., Reciprocal relationship between insulin resistance and endothelial dysfunction: molecular pathophysiological mechanisms, Circulation, 2006, 113, 1888–1904
Rosano G.M., Sheiban I., Massaro R., Pagnotta P., Marazzi G., Vitale C., et al., Low testosterone levels are associated with coronary artery disease in male patients with angina, Int. J. Impot. Res., 2007, 19, 176–182
Vryonidou A., Papatheodorou A., Tavridou A., Terzi T., Loi V., Vatalas I.A., et al., Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 2740–2746
Dagre A., Lekakis J., Mihas C., Protogerou A., Thalassinou L., Tryfonopoulos D., et al., Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome, Eur. J. Endocrinol., 2006, 154, 883–890
Worboys S., Kotsopoulos D., Teede H., McGrath B., Davis S.R., Evidence that parenteral testosterone therapy may improve endothelium-dependent and-independent vasodilation in postmenopausal women already receiving estrogen, J. Clin. Endocrinol. Metab., 2001, 86, 158–161
Zhang Z., Wang L., Dou Y., Zhao J., Jiang T., Qiao Z., et al., Testosterone and estradiol modulate TNFalpha-induced expression of adhesion molecules in endothelial cells, Methods Find. Exp. Clin. Pharmacol., 2002, 24, 125–30
McChrohon J.A., Jessup W., Handelsmann D.J., Celermajer D.S., Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1, Circulation, 1999, 99, 2317–2322
Death A.K., McGrath K., Sader M., Nakhla S., Jessup W., Handelsman D.J., et al. Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor-?B-dependent patway, Endocrinology, 2004, 145,1889–1897
Gooren L.J., Giltay E.J., Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females, J. Sex. Med., 2008, 5, 765–76
Elbers J.M., Giltay E.J., Teerlink T., Scheffer P.G., Asscheman H., Seidell J.C., et al., Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects, Clin. Endocrinol. (Oxf), 2003, 58, 562–71
Berra M., Armillotta F., D’Emidio L., Costantino A., Martorana G., Pelusi G., et al., Testosterone decreases adiponectin levels in female to male transsexuals, Asian J. Androl., 2006, 8, 725–729
McCredie R.J., McCrohon J.A., Turner L., Griffiths K.A., Handelsman D.J., Celermajer D.S., Vascular reactivity is impaired in genetic females taking high-dose androgens, J. Am. Coll. Cardiol., 1998, 32, 1331–1335
Simoncini T., Mannella P., Fornari L., Varone G., Caruso A., Genazzani A.R., Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms, Endocrinology, 2003, 144, 3449–3455
Williams M.R.I., Ling S., Dawood T., Hshimura K., Dai A., Li H., et al., Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs, J. Clin. Endocrinol. Metab., 2002, 87, 176–181
Liu D., Dillon J.S., Dehydroepiandroterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor, The Journal of Biological Chemistry, 2002, 24, 21379–21388
Liu D., Dillon J.S., Dehydroepiandroterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor, Steroids, 2004, 69, 279–89
Formoso G., Chen H., Kim J., Montagnani M., Consoli A., Quon M.J., Dehydroepiandroterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin 1 via distinct phosphatidylinositol 3-kinase and mitogenactivated protein kinase-dependent pathways in vascular endothelium, Molecular Endocrinology, 2006, 20, 1153–1163
Ibanez L., de Zegher F., Ethinylestradiol-drospire-none, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity, J. Clin. Endocrinol. Metab., 2004, 89, 592–1597
Cho L.W., Randeva H.S., Atkin S.L., Cardiometabolic aspects of polycystic ovarian syndrome, Vasc. Health Risk Manag., 2007, 3, 55–63
Ouedraogo R., Gong Y., Berzins B., Wu X., Mahadev K., Hough K., et al., Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo, J. Clin. Investig., 2007, 117, 1718–1726
Escobar-Morreale H.F., Villuendas G., Botella-Carretero J.I., Álvarez-Blasco F., Sanchón R., Luque-Ramírez M., Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study, Human Reproduction, 2006, 21, 2257–2265
Ardawi M.S., Rouzi A.A., Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome, Fertil. Steril., 2005, 83, 1708–1716
Ducluzeau P.H., Cousin P., Malvoisin E., Bornet H., Vidal H., Laville M., et al., Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2003, 88, 3626–3631
Gulcelik N.E., Aral Y., Serter R., Koc G., Association of hypoadiponectinemia with metabolic syndrome in patients with polycystic ovary syndrome, J. Natl. Med. Assoc., 2008, 100, 64–68
Bik W., Baranowska-Bik A., Wolinska-Witort E., Chmielowska M., Martynska L., Baranowska B., The relationship between metabolic status and levels of adiponectin and ghrelin in lean women with polycystic ovary syndrome, Gynecol. Endocrinol., 2007, 23, 325–331
Escobar-Moreale H.F., San Millan J.L., Abdominal adiposity and the polycystic ovary syndrome, Trends in Endocrinology and Metabolism, 2007, 18, 266–272
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Ilie, I.R., Pepene, C.E., Duncea, I. et al. Vascular abnormalities and low-grade chronic inflammation in women with polycystic ovary syndrome: Relationships with insulin resistance, obesity and hyperandrogenemia. cent.eur.j.med 3, 257–270 (2008). https://doi.org/10.2478/s11536-008-0044-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2478/s11536-008-0044-8